First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

被引：54

作者：

Banerjee, Susana ^{[1
,2
]}

Gonzalez-Martin, Antonio ^{[3
]}

Harter, Philipp ^{[4
]}

Lorusso, Domenica ^{[5
]}

Moore, Kathleen N. ^{[6
]}

Oaknin, Ana ^{[7
]}

Ray-Coquard, Isabelle ^{[8
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Gynaecol Unit, London, England

[2] Inst Canc Res, London, England

[3] Clin Univ Navarra, Madrid, Spain

[4] Ev Kliniken Essen Mitte, Dept Gynaecol & Gynaecol Oncol, Essen, Germany

[5] Fdn Policlin Univ Agostino Gemelli, Sci Directorate & Gynecol Oncol Unit, Rome, Italy

[6] Univ Oklahoma, Stephenson Canc Ctr, Norman, OK 73019 USA

[7] Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

[8] Univ Claude Bernard Lyon, Ctr Leon Berard, Lyon, France

来源：

ESMO OPEN | 2020年 / 5卷 / 06期

关键词：

PARP inhibitors; advanced ovarian cancer; MAINTENANCE THERAPY; EPITHELIAL OVARIAN; DOUBLE-BLIND; BEVACIZUMAB; OLAPARIB; OUTCOMES; TRIAL;

D O I：

10.1136/esmoopen-2020-001110

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Administration approval of olaparib as first-line maintenance therapy in patients with BRCA1/2 mutation, establishing a new standard of care. Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with BRCA1/2 mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib irrespective of biomarker status and olaparib in combination with bevacizumab in homologous recombination deficiency-positive-associated advanced ovarian cancer. An ESMO Open - Cancer Horizons round-table expert panel discussed the four phase III trials of first-line PARP inhibitor therapy and how they are changing the clinical management of advanced ovarian cancer.

引用

页数：10

共 40 条

[1] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2] Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study [J].

Ang, Joo Ern ;

Gourley, Charlie ;

Powell, C. Bethan ;

High, Hilda ;

Shapira-Frommer, Ronnie ;

Castonguay, Vincent ;

De Greve, Jacques ;

Atkinson, Tina ;

Yap, Timothy A. ;

Sandhu, Shahneen ;

Banerjee, Susana ;

Chen, Lee-May ;

Friedlander, Michael L. ;

Kaufman, Bella ;

Oza, Amit M. ;

Matulonis, Ursula ;

Barber, Louise J. ;

Kozarewa, Iwanka ;

Fenwick, Kerry ;

Assiotis, Ioannis ;

Campbell, James ;

Chen, Lina ;

de Bono, Johann S. ;

Gore, Martin E. ;

Lord, Christopher J. ;

Ashworth, Alan ;

Kaye, Stan B. .

CLINICAL CANCER RESEARCH, 2013, 19 (19) :5485-5493

[3]

[Anonymous], ANN ONCOL

[4] Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1 [J].

Banerjee, S. ;

Moore, K. N. ;

Colombo, N. ;

Scambia, G. ;

Kim, B-G. ;

Oaknin, A. ;

Friedlander, M. ;

Lisyanskaya, A. ;

Floquet, A. ;

Leary, A. ;

Sonke, G. S. ;

Gourley, C. ;

Oza, A. ;

Gonzalez Martin, A. ;

Aghajanian, C. ;

Bradley, W. ;

Holmes, E. ;

Lowe, E. S. ;

DiSilvestro, P. .

ANNALS OF ONCOLOGY, 2020, 31 :S613-S613

[5] First-line PARP inhibition in ovarian cancer - standard of care for all? [J].

Banerjee, Susana N. ;

Lord, Christopher J. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (03) :136-137

[6] Safety and dose modification for patients receiving niraparib (vol 29, pg 1784, 2018) [J].

Berek, J. S. ;

Matulonis, U. A. ;

Peen, U. ;

Ghatage, P. ;

Mahner, S. ;

Redondo, A. ;

Lesoin, A. ;

Colombo, N. ;

Vergote, I. ;

Rosengarten, O. ;

Ledermann, J. ;

Pineda, M. ;

Ellard, S. ;

Sehouli, J. ;

Gonzalez-Martin, A. ;

Berton-Rigaud, D. ;

Madry, R. ;

Reinthaller, A. ;

Hazard, S. ;

Guo, W. ;

Mirza, M. R. .

ANNALS OF ONCOLOGY, 2019, 30 (05) :859-859

[7] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[8] Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome [J].

Cecere, Sabrina Chiara ;

Giannone, Gaia ;

Salutari, Vanda ;

Arenare, Laura ;

Lorusso, Domenica ;

Ronzino, Graziana ;

Lauria, Rossella ;

Cormio, Gennaro ;

Carella, Claudia ;

Scollo, Paolo ;

Ghizzoni, Viola ;

Raspagliesi, Francesco ;

Di Napoli, Marilena ;

Mazzoni, Enrica ;

Marchetti, Claudia ;

Bergamini, Alice ;

Orditura, Michele ;

Valabrega, Giorgio ;

Scambia, Giovanni ;

Maltese, Giuseppa ;

De Matteis, Elisabetta ;

Cardalesi, Cinzia ;

Loizzi, Vera ;

Boccia, Serena ;

Naglieri, Emanuele ;

Scandurra, Giuseppa ;

Pignata, Sandro .

GYNECOLOGIC ONCOLOGY, 2020, 156 (01) :38-44

[9] Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer [J].

Coleman, R. L. ;

Fleming, G. F. ;

Brady, M. F. ;

Swisher, E. M. ;

Steffensen, K. D. ;

Friedlander, M. ;

Okamoto, A. ;

Moore, K. N. ;

Ben-Baruch, N. Efrat ;

Werner, T. L. ;

Cloven, N. G. ;

Oaknin, A. ;

DiSilvestro, P. A. ;

Morgan, M. A. ;

Nam, J. -H. ;

Leath, C. A., III ;

Nicum, S. ;

Hagemann, A. R. ;

Littell, R. D. ;

Cella, D. ;

Baron-Hay, S. ;

Garcia-Donas, J. ;

Mizuno, M. ;

Bell-McGuinn, K. ;

Sullivan, D. M. ;

Bach, B. A. ;

Bhattacharya, S. ;

Ratajczak, C. K. ;

Ansell, P. J. ;

Dinh, M. H. ;

Aghajanian, C. ;

Bookman, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25) :2403-2415

[10]

Du Bois A, 2020, J CLIN ONCOL, V38

← 1 2 3 4 →